Baidu
map

Cancer Biomark.:吴一龙教授发现GLI3TR表达情况与NSCLC患者预后有关

2013-06-08 Cancer Biomark dxy

在2013年1月1日出版的《 Cancer Biomark》杂志上,发表了我国广东省人民医院吴一龙教授等人的一项研究结果,该研究对非小细胞肺癌(NSCLC)患者的GLI3表达情况进行了评价。研究人员同时对GLI3在肺部癌变中的作用及其与NSCLC患者临床病理因素和总生存率(OS)间的关系进行了考察。Hedgehog信号通路(Hh)参与胚胎发育及器官形成过程。GLI3则是Hh信号通路中的一种锌指转录

在2013年1月1日出版的《 Cancer Biomark》杂志上,发表了我国广东省人民医院吴一龙教授等人的一项研究结果,该研究对非小细胞肺癌(NSCLC)患者的GLI3表达情况进行了评价。研究人员同时对GLI3在肺部癌变中的作用及其与NSCLC患者临床病理因素和总生存率(OS)间的关系进行了考察。Hedgehog信号通路(Hh)参与胚胎发育及器官形成过程。GLI3则是Hh信号通路中的一种锌指转录因子,其存在形式有全长型(GLI3FL)及截短型(GLI3TR)两类。

研究人员通过免疫组化法,分别对330份及352份NSCLC可评价组织样本的GLI3FL和GLI3TR表达情况进行了分析。并利用统计学方法,对GLI3FL与GLI3TR表达情况与临床病理参数和OS间的关系进行了分析。

研究结果表明,通过免疫组化染色,可观察到恶性上皮细胞细胞质内的GLI3FL,在核区则可观察到GLI3TR。GLI3FL及GLI3TR的表达水平较高,分别为52.7%及45.2%。GLI3FL与临床病理参数及患者生存间并无显著关联。然而GLI3TR高表达与淋巴结转移(P=0.013)及较差OS(28.4 vs. 40.8个月, P=0.010)间存在显著关联。对于GLI3TR表达水平较高及较低的腺癌患者,其中位OS分别为25.7个月及50.6个月(P=0.004)。而多变量分析表明,GLI3TR表达水平(P=0.036)、肿瘤分化情况(P< 0.001)、病情分期(P < 0.001)为NSCLC患者预后的独立预测因素。

吴教授等人最终认为,NSCLC患者,尤其是腺癌患者的GLI3TR过量表达与较差预后有关。GLI3TR表达情况为OS相关的独立预后因素。同时,GLI3TR可能在NSCLC癌变过程中发挥重要作用。

Identification of asbestos fibers within single cells.
Abstract
Identification of asbestos fibers and other mineral particles in tissues is important for the diagnosis of interstitial lung disease. Conventional procedures to identify mineral particles are applicable to tissue digests, homogenates, or thin sections prepared for transmission electron microscopy. Positive identification of mineral particles in these samples is achieved by energy dispersive x-ray analysis or crystalline diffraction patterns. These analytical techniques are difficult to use for identification of long, thin asbestos fibers within cells collected from effusions or by saline lavage. A new preparative procedure is presented which allows intracellular visualization of fibers in these samples. Mice were injected intraperitoneally with 100 micrograms of crocidolite asbestos. After 1 to 30 days, the free peritoneal cell population was collected by saline lavage and allowed to attach to Formvar/carbon coated grids in vitro. Cell spreading was induced by exposure to phorbol-12-myristate-13-acetate for an additional 4 hours. The flattened cells were fixed, dehydrated and air-dried before examination by transmission electron microscopy. This procedure allows direct visualization of intracellular fibers. The characteristic Fe and Si peaks of crocidolite asbestos were confirmed by energy dispersive x-ray analysis. This technique was used to study the kinetics of clearance of asbestos fibers from the free peritoneal macrophage population of mice.

版权声明:
本网站所有内容来源注明为“梅斯医学”或“MedSci原创”的文字、图片和音视频资料,版权均属于梅斯医学所有。非经授权,任何媒体、网站或个人不得转载,授权转载时须注明来源为“梅斯医学”。其它来源的文章系转载文章,或“梅斯号”自媒体发布的文章,仅系出于传递更多信息之目的,本站仅负责审核内容合规,其内容不代表本站立场,本站不负责内容的准确性和版权。如果存在侵权、或不希望被转载的媒体或个人可与我们联系,我们将立即进行删除处理。
在此留言
评论区 (4)
#插入话题
  1. [GetPortalCommentsPageByObjectIdResponse(id=2068926, encodeId=fc5b20689266b, content=<a href='/topic/show?id=bbd816043f2' target=_blank style='color:#2F92EE;'>#SCLC患者#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=74, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=16043, encryptionId=bbd816043f2, topicName=SCLC患者)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=44a360, createdName=jklm09, createdTime=Wed Jun 12 15:35:00 CST 2013, time=2013-06-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1691806, encodeId=70c71691806ac, content=<a href='/topic/show?id=a450530853c' target=_blank style='color:#2F92EE;'>#患者预后#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=81, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=53085, encryptionId=a450530853c, topicName=患者预后)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=8f4729287700, createdName=bnurmamat, createdTime=Thu Oct 24 00:35:00 CST 2013, time=2013-10-24, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1916960, encodeId=b07b191696005, content=<a href='/topic/show?id=4f26341994' target=_blank style='color:#2F92EE;'>#Bio#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=53, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=3419, encryptionId=4f26341994, topicName=Bio)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=12de429, createdName=sunylz, createdTime=Wed Jun 26 03:35:00 CST 2013, time=2013-06-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1410784, encodeId=e75d1410e84bb, content=<a href='/topic/show?id=a4ed130e7d0' target=_blank style='color:#2F92EE;'>#NSCLC患者#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=57, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=13077, encryptionId=a4ed130e7d0, topicName=NSCLC患者)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=06332789533, createdName=xiongliangxl, createdTime=Mon Jun 10 05:35:00 CST 2013, time=2013-06-10, status=1, ipAttribution=)]
    2013-06-12 jklm09
  2. [GetPortalCommentsPageByObjectIdResponse(id=2068926, encodeId=fc5b20689266b, content=<a href='/topic/show?id=bbd816043f2' target=_blank style='color:#2F92EE;'>#SCLC患者#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=74, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=16043, encryptionId=bbd816043f2, topicName=SCLC患者)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=44a360, createdName=jklm09, createdTime=Wed Jun 12 15:35:00 CST 2013, time=2013-06-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1691806, encodeId=70c71691806ac, content=<a href='/topic/show?id=a450530853c' target=_blank style='color:#2F92EE;'>#患者预后#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=81, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=53085, encryptionId=a450530853c, topicName=患者预后)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=8f4729287700, createdName=bnurmamat, createdTime=Thu Oct 24 00:35:00 CST 2013, time=2013-10-24, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1916960, encodeId=b07b191696005, content=<a href='/topic/show?id=4f26341994' target=_blank style='color:#2F92EE;'>#Bio#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=53, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=3419, encryptionId=4f26341994, topicName=Bio)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=12de429, createdName=sunylz, createdTime=Wed Jun 26 03:35:00 CST 2013, time=2013-06-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1410784, encodeId=e75d1410e84bb, content=<a href='/topic/show?id=a4ed130e7d0' target=_blank style='color:#2F92EE;'>#NSCLC患者#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=57, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=13077, encryptionId=a4ed130e7d0, topicName=NSCLC患者)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=06332789533, createdName=xiongliangxl, createdTime=Mon Jun 10 05:35:00 CST 2013, time=2013-06-10, status=1, ipAttribution=)]
  3. [GetPortalCommentsPageByObjectIdResponse(id=2068926, encodeId=fc5b20689266b, content=<a href='/topic/show?id=bbd816043f2' target=_blank style='color:#2F92EE;'>#SCLC患者#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=74, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=16043, encryptionId=bbd816043f2, topicName=SCLC患者)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=44a360, createdName=jklm09, createdTime=Wed Jun 12 15:35:00 CST 2013, time=2013-06-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1691806, encodeId=70c71691806ac, content=<a href='/topic/show?id=a450530853c' target=_blank style='color:#2F92EE;'>#患者预后#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=81, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=53085, encryptionId=a450530853c, topicName=患者预后)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=8f4729287700, createdName=bnurmamat, createdTime=Thu Oct 24 00:35:00 CST 2013, time=2013-10-24, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1916960, encodeId=b07b191696005, content=<a href='/topic/show?id=4f26341994' target=_blank style='color:#2F92EE;'>#Bio#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=53, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=3419, encryptionId=4f26341994, topicName=Bio)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=12de429, createdName=sunylz, createdTime=Wed Jun 26 03:35:00 CST 2013, time=2013-06-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1410784, encodeId=e75d1410e84bb, content=<a href='/topic/show?id=a4ed130e7d0' target=_blank style='color:#2F92EE;'>#NSCLC患者#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=57, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=13077, encryptionId=a4ed130e7d0, topicName=NSCLC患者)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=06332789533, createdName=xiongliangxl, createdTime=Mon Jun 10 05:35:00 CST 2013, time=2013-06-10, status=1, ipAttribution=)]
    2013-06-26 sunylz
  4. [GetPortalCommentsPageByObjectIdResponse(id=2068926, encodeId=fc5b20689266b, content=<a href='/topic/show?id=bbd816043f2' target=_blank style='color:#2F92EE;'>#SCLC患者#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=74, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=16043, encryptionId=bbd816043f2, topicName=SCLC患者)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=44a360, createdName=jklm09, createdTime=Wed Jun 12 15:35:00 CST 2013, time=2013-06-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1691806, encodeId=70c71691806ac, content=<a href='/topic/show?id=a450530853c' target=_blank style='color:#2F92EE;'>#患者预后#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=81, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=53085, encryptionId=a450530853c, topicName=患者预后)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=8f4729287700, createdName=bnurmamat, createdTime=Thu Oct 24 00:35:00 CST 2013, time=2013-10-24, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1916960, encodeId=b07b191696005, content=<a href='/topic/show?id=4f26341994' target=_blank style='color:#2F92EE;'>#Bio#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=53, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=3419, encryptionId=4f26341994, topicName=Bio)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=12de429, createdName=sunylz, createdTime=Wed Jun 26 03:35:00 CST 2013, time=2013-06-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1410784, encodeId=e75d1410e84bb, content=<a href='/topic/show?id=a4ed130e7d0' target=_blank style='color:#2F92EE;'>#NSCLC患者#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=57, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=13077, encryptionId=a4ed130e7d0, topicName=NSCLC患者)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=06332789533, createdName=xiongliangxl, createdTime=Mon Jun 10 05:35:00 CST 2013, time=2013-06-10, status=1, ipAttribution=)]

相关资讯

Thorax:肺癌术后早期死亡率与年龄相关

  英国学者的一项研究显示,年龄是预测术后早期死亡率的最重要因子。相关论文2013年5月17日在线发表于《喉》杂志 。。   该研究纳入在2004-2010年期间手术的10991例非小细胞肺癌(NSCLC)患者的资料,了解其术后30-90天的死亡率。我们量化了术后早期死亡率的预测因子,并使用这些结果设计出一个得分来预测术后90天的死亡风险。   结果显示,3%(334例)的患者在术后

晚期肺癌30年来治疗变革

    时隔30年,美国的临床肿瘤杂志(JCO)在2013-3-10日再次发表肺癌专辑,美国德克萨斯大学西南医学中心的Joan H. Schiller博士、加利福尼亚大学综合癌症中心的David R. Gandara博士等人撰写文章总结了肺癌近30年的发展历程。让我们看到人类与疾病抗争的艰辛历程。这里也根据自己所知道的一些片段写出来和大家分享。小细胞肺癌:EP方案,唯

晚期非小细胞肺癌EGFR-TKI失败后治疗策略

近年来,涉及表皮生长因子受体(EGFR)-酪氨酸激酶抑制剂(TKI,吉非替尼和厄洛替尼)治疗晚期非小细胞肺癌(NSCLC) 的各类研究层见叠出,证据亦越来越多。各类指南推荐的TKI治疗范围涵盖了晚期NSCLC的二、三线治疗,一线治疗甚至维持治疗,由此推断极大比例的晚期 NSCLC患者在其治疗过程中的某个阶段必然会接受EGFR-TKI治疗。但是,无论近期疗效如何,最终患者都会不可避免地出现对TK

ASCO 2013:培美曲塞二线治疗EGFR野生型NSCLC优于吉非替尼

背景: 培美曲塞或吉非替尼为东亚地区晚期非鳞NSCLC患者二线治疗的常规治疗手段。CTONG 0806研究为一项多中心、随机对照、开放标签的II期临床试验,该试验针对无EGFR突变的晚期NSCLC患者,旨在对培美曲塞与吉非替尼用于二线治疗时的疗效进行对比考察。 方法:本研究招募对象为局部晚期或转移性非鳞NSCLC患者,患者此前曾接受过铂制剂为基础的化疗,且第18-21外显子不存在EGFR突变。患

ASCO 2013:中山大学张力教授确定亚洲NSCLC人群进行多西他赛维持治疗更佳剂量

背景: 根据相关报告,多西他赛(75 mg/m 2 )可用于西方晚期NSCLC患者群的一线和维持治疗。而目前亚洲患者在进行多西他赛治疗时,用药剂量却有所不同(60 mg/m 2 )。这种差异或可通过不同种族间在紫杉醇代谢方面的药物遗传变异予以解释。TFINE研究对多西他赛维持治疗的药效、安全性以及耐受性进行了评价,同时本研究也试图确定亚组人群在进行多西他赛治疗时的最佳剂量。 方法:本研究入选人群

非小细胞肺癌(NSCLC)的是否需要维持治疗?

    最近几年,在各种的学术会议上,肺癌的医生都在讨论一个热点问题:晚期非小细胞肺癌一线治疗结束后,需不需要维持治疗?如果需要,是同药维持,还是换药维持?   其实,关于维持治疗的讨论这已经不是第一次,关于肿瘤化学治疗的周期数的问题,在化疗诞生伊始,就发生过激烈的讨论。毕业于中国沈阳盛京医学院的李敏求(Min Chiu Lee)在美国国立癌症研究所(NCI

Baidu
map
Baidu
map
Baidu
map